Combination of Factor H Mutation and Properdin Deficiency Causes Severe C3 Glomerulonephritis

Factor H (fH) and properdin both modulate complement; however, fH inhibits activation, and properdin promotes activation of the alternative pathway of complement. Mutations in fH associate with several human kidney diseases, but whether inhibiting properdin would be beneficial in these diseases is u...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Society of Nephrology 2013-01, Vol.24 (1), p.53-65
Main Authors: LESHER, Allison M, LIN ZHOU, HAMANO, Takayuki, MIWA, Takashi, TUNG, Kenneth S, SONG, Wen-Chao, KIMURA, Yuko, SATO, Sayaka, GULLIPALLI, Damodar, HERBERT, Andrew P, BARLOW, Paul N, EBERHARDT, Hannes U, SKERKA, Christina, ZIPFEL, Peter F
Format: Article
Language:English
Subjects:
Animals
Basic Research
Biological and medical sciences
Complement C3 - metabolism
Complement Factor H - deficiency
Complement Factor H - genetics
Complement Pathway, Alternative
Disease Models, Animal
Glomerulonephritis
Glomerulonephritis, Membranoproliferative - genetics
Glomerulonephritis, Membranoproliferative - metabolism
Glomerulonephritis, Membranoproliferative - pathology
Humans
Kidney Diseases - genetics
Kidney Glomerulus - ultrastructure
Medical sciences
Mice
Mice, Inbred C57BL
Mutation
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
Properdin - deficiency
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Factor H (fH) and properdin both modulate complement; however, fH inhibits activation, and properdin promotes activation of the alternative pathway of complement. Mutations in fH associate with several human kidney diseases, but whether inhibiting properdin would be beneficial in these diseases is unknown. Here, we found that either genetic or pharmacological blockade of properdin, which we expected to be therapeutic, converted the mild C3 GN of an fH-mutant mouse to a lethal C3 GN with features of human dense deposit disease. We attributed this phenotypic change to a differential effect of properdin on the dynamics of alternative pathway complement activation in the fluid phase and the cell surface in the fH-mutant mice. Thus, in fH mutation-related C3 glomerulopathy, additional factors that impact the activation of the alternative pathway of complement critically determine the nature and severity of kidney pathology. These results show that therapeutic manipulation of the complement system requires rigorous disease-specific target validation.
ISSN:1046-6673
1533-3450
DOI:10.1681/asn.2012060570